NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
J Clin Virol
; 82: 66-69, 2016 09.
Article
em En
| MEDLINE
| ID: mdl-27454231
ABSTRACT
Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir+ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co-infected patient with cirrhosis.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Ribavirina
/
Benzimidazóis
/
Hepacivirus
/
Hepatite C Crônica
/
Farmacorresistência Viral
/
Fluorenos
/
Sofosbuvir
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article